Analysts Set Viridian Therapeutics, Inc. (NASDAQ:VRDN) Price Target at $35.70

Shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN - Get Free Report) have been assigned a consensus recommendation of "Moderate Buy" from the twelve research firms that are covering the stock, MarketBeat.com reports. Three analysts have rated the stock with a hold recommendation and nine have issued a buy recommendation on the company. The average 1-year price target among brokers that have issued a report on the stock in the last year is $35.70.

A number of analysts recently issued reports on VRDN shares. Royal Bank of Canada increased their price objective on Viridian Therapeutics from $44.00 to $47.00 and gave the stock an "outperform" rating in a report on Tuesday, December 17th. Wells Fargo & Company reissued an "equal weight" rating and set a $27.00 price objective (down previously from $37.00) on shares of Viridian Therapeutics in a report on Thursday, December 19th. TD Cowen started coverage on Viridian Therapeutics in a report on Monday, November 25th. They set a "buy" rating on the stock. HC Wainwright reissued a "buy" rating and set a $34.00 price objective on shares of Viridian Therapeutics in a report on Monday, December 16th. Finally, Needham & Company LLC reissued a "buy" rating and set a $38.00 price objective on shares of Viridian Therapeutics in a report on Tuesday, January 7th.

Viridian Therapeutics Stock Down 0.1 %

Shares of NASDAQ VRDN opened at $15.53 on Friday. The business's fifty day moving average price is $18.34 and its 200-day moving average price is $19.66. The stock has a market capitalization of $1.23 billion, a PE ratio of -3.60 and a beta of 1.32. The company has a debt-to-equity ratio of 0.04, a current ratio of 18.55 and a quick ratio of 18.55. Viridian Therapeutics has a one year low of $11.40 and a one year high of $27.20.

Remove Ads

Hedge Funds Weigh In On Viridian Therapeutics

Institutional investors have recently modified their holdings of the company. R Squared Ltd bought a new position in shares of Viridian Therapeutics during the 4th quarter valued at about $26,000. Foresite Capital Management VI LLC bought a new stake in shares of Viridian Therapeutics in the 4th quarter worth approximately $38,000. AlphaQuest LLC lifted its stake in shares of Viridian Therapeutics by 119.0% in the 4th quarter. AlphaQuest LLC now owns 2,795 shares of the company's stock valued at $54,000 after purchasing an additional 1,519 shares during the period. Point72 Asia Singapore Pte. Ltd. purchased a new position in shares of Viridian Therapeutics in the 3rd quarter valued at approximately $149,000. Finally, Summit Investment Advisors Inc. lifted its stake in shares of Viridian Therapeutics by 24.7% in the 4th quarter. Summit Investment Advisors Inc. now owns 7,646 shares of the company's stock valued at $147,000 after purchasing an additional 1,516 shares during the period.

Viridian Therapeutics Company Profile

Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.